Australia markets open in 6 hours 15 minutes

Mustang Bio, Inc. (MBIO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2771+0.0101 (+3.78%)
As of 01:44PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.2670
Open0.2699
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.2699 - 0.2800
52-week range0.2200 - 8.1700
Volume113,502
Avg. volume238,883
Market cap2.879M
Beta (5Y monthly)1.54
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Mustang Bio Announces Pricing of $4 Million Public Offering

    WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the pricing of a public offering of an aggregate of 16,877,638 shares of its common stock (or common stock equivalents in lieu thereof), Series A-1 warrants to purcha

  • GlobeNewswire

    Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

    Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth quarter of 2024 MB-106 data in B-cell non-Hodgkin lymphoma (NHL) provide a strong foundation for future development in autoimmune disease; pivotal trial for Waldenstrom macroglobulinemia (WM) is expected to initiate in the second half of 2024 WORCESTER, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Mus

  • GlobeNewswire

    Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

    WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023. "2023 was an exciting year for Mustang filled with many highlights, inclu